Aardvark Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing small-molecule therapies for metabolic diseases. Recent 8-K reports cover financial results, pipeline and business updates, ARD-101 HERO trial disclosures in Prader-Willi Syndrome, ARD-201 obesity program updates, clinical protocol matters, and corporate presentation materials.
The filing record also includes capital-structure disclosures tied to a shelf registration statement and equity distribution agreement, governance and executive-transition matters, compensatory arrangements, and the role of Ardia Therapeutics as a wholly owned subsidiary supporting Aardvark's dermatology pipeline.
Aardvark Therapeutics disclosed that the U.S. Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101. The hold covers all ongoing studies, including the Phase 3 HERO trial in Prader-Willi Syndrome and its open-label extension.
The company is in active discussions with the FDA and plans to unblind accumulated data from both HERO and the OLE trial to evaluate overall safety and efficacy and guide next steps for the ARD-101 program. As of February 27, 2026, 68 patients had been dosed in HERO and 19 in the OLE trial.
As of March 31, 2026, Aardvark reported $91.2 million in cash, cash equivalents and short-term investments, which it believes will fund projected operations into mid-2027 while it assesses ARD-101 and continues its broader hunger- and metabolic-disease pipeline.
Aardvark Therapeutics reported a net loss of $21.6 million for the quarter ended March 31, 2026, wider than the $9.3 million loss a year earlier, driven by sharply higher research and development and general and administrative expenses.
R&D spending more than doubled to $16.6 million as the company advanced lead candidate ARD-101 and related programs, while G&A expenses rose to $5.9 million as it scaled public-company operations. Aardvark ended the quarter with $91.2 million in cash, cash equivalents and short-term investments and an accumulated deficit of $137.5 million, and believes this liquidity can fund operations into mid-2027.
On February 27, 2026, the company voluntarily paused enrollment and dosing in its Phase 3 HERO and open-label extension trials for ARD-101, as well as the Phase 2 POWER and STRENGTH trials for ARD-201, after reversible cardiac observations in a healthy volunteer study of ARD-101. Aardvark is reviewing the data and working with the FDA to determine next steps, with guidance expected in the second quarter of 2026.
Aardvark Therapeutics reported first quarter 2026 results and detailed a voluntary pause of its lead clinical programs. The Phase 3 HERO and open-label extension trials of ARD-101 in Prader-Willi Syndrome, and development of ARD-201 for obesity, are on hold after reversible cardiac observations in a separate healthy volunteer study.
The company is working with the FDA and expects further guidance on both programs in the second quarter of 2026. Aardvark ended March 31, 2026 with $91.2 million in cash, cash equivalents and short-term investments, which it believes will fund operations into mid-2027.
First quarter 2026 research and development expenses rose to $16.6 million from $7.8 million a year earlier, while general and administrative costs increased to $5.9 million from $2.7 million, reflecting higher ARD-101 development and public company costs. Net loss widened to $21.6 million, or $0.99 per share, compared with a $9.3 million loss, or $0.71 per share, in the prior-year period.
Aardvark Therapeutics, Inc. filed a prospectus to sell up to $150,000,000 of common stock through an Equity Distribution Agreement with Piper Sandler as an at-the-market sales agent. Sales may occur from time to time under the agreement at market prices.
The prospectus cites an assumed offering price of $4.07 per share (closing price on March 20, 2026) and uses proceeds for general corporate purposes. The company discloses key clinical programs for ARD-101 (HERO Phase 3) and ARD-201 (POWER and STRENGTH Phase 2 trials) and states those trials are currently paused while it reviews reversible cardiac observations and collaborates with the FDA on next steps.
Aardvark Therapeutics, Inc. entered into an Equity Distribution Agreement with Piper Sandler & Co. allowing it to sell, from time to time, shares of its common stock through or to Piper Sandler as sales agent. These shares will be issued under an existing shelf registration statement on Form S-3.
Under the related prospectus, the company may offer and sell shares with an aggregate offering price of up to $150,000,000. Piper Sandler will receive a commission of 3.0% of the gross sales price per share sold. Aardvark has no obligation to sell any shares under this arrangement.
Aardvark Therapeutics, Inc. is registering up to $400,000,000 of securities under a shelf registration, including up to $150,000,000 of its common stock that may be sold under an Equity Distribution Agreement with Piper Sandler & Co.
The prospectus covers common stock, preferred stock, debt securities, warrants, rights, units and depositary shares to be offered from time to time. The company’s common stock trades on Nasdaq under the symbol AARD and had a last reported sale price of $4.07 per share on March 20, 2026. The filing discloses that on February 27, 2026, Aardvark voluntarily paused enrollment and dosing in its HERO and OLE trials following reversible cardiac observations in a healthy volunteer study and is collaborating with the FDA to determine next steps; related ARD-201 trials are also paused while safety assessments continue.
Aardvark Therapeutics is a clinical-stage biopharma company developing small-molecule drugs that activate bitter taste receptors (TAS2Rs) to modulate hunger pathways for metabolic diseases. Its lead oral candidate, ARD-101, targets hyperphagia in Prader-Willi syndrome (PWS) via gut-localized CCK and GLP-1 release with minimal systemic exposure.
Phase 1 in healthy volunteers and an open-label Phase 2 PWS study showed ARD-101 was generally well-tolerated and reduced validated hyperphagia questionnaire scores, with trends toward lower body fat and higher lean mass. ARD-101 holds FDA Orphan Drug and Rare Pediatric Disease designations for PWS.
Aardvark started the Phase 3 HERO trial in December 2024 but voluntarily paused enrollment and dosing in February 2026 after reversible QRS prolongation was observed in a healthy volunteer cardiac safety study at high doses. Related ARD-201 Phase 2 POWER and planned STRENGTH obesity trials are also paused. The company is reviewing safety data and redesign options with the FDA and no longer expects HERO topline data in the third quarter of 2026, with further guidance planned in the second quarter of 2026.
Aardvark Therapeutics reported fourth quarter and full-year 2025 results and announced significant pipeline changes. The company has voluntarily paused enrollment and dosing in its Phase 3 HERO and OLE trials of ARD-101 for Prader-Willi Syndrome, and also paused its ARD-201 obesity trials, after reversible cardiac QRS prolongation was seen in high-dose healthy volunteer studies. Aardvark is working with the FDA and expects further guidance on both programs in the second quarter of 2026. As of December 31, 2025, it held $110.0 million in cash, cash equivalents and short-term investments, which it believes will fund operations into the second quarter of 2027. Full-year 2025 R&D expenses rose to $48.9 million and G&A expenses to $13.8 million, driving a net loss of $57.6 million, compared with a net loss of $20.6 million in 2024. The company also highlighted published clinical and preclinical ARD-101 data showing reduced hunger scores and favorable gut hormone changes in prior studies.
Aardvark Therapeutics has voluntarily paused its Phase 3 HERO trial of ARD-101 in Prader-Willi syndrome, along with the related open-label extension. The pause follows reversible cardiac observations at above target therapeutic doses seen during routine safety monitoring in a healthy volunteer study.
The company is conducting a comprehensive data review and has temporarily halted enrollment and dosing in HERO out of caution. As a result, Aardvark no longer expects to report topline HERO data in the third quarter of 2026 and plans to give updated timing guidance in the second quarter of this year.